Physician profile
Hubert M Landers
NPI 1538189634
$6,951.41
in general payments reported to CMS, 2019-2025
37 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $1,433 · 2021: $1,586 · 2022: $1,031 · 2023: $836 · 2024: $429 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,239.67 | 2019-2025 | |
| Amarin Pharma, INC. | $780.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $763.77 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $684.92 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $560.21 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $500.83 | 2021-2025 | |
| Astellas Pharma US INC | $348.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $329.20 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.76 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $215.93 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $136.97 | 2019-2024 | |
| Esperion Therapeutics, INC. | $135.99 | 2020-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $108.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $88.10 | 2021-2023 | Eliquis |
| Eisai INC. | $79.13 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hubert Landers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.